Combination Therapy Extends Crohn's Treatment Durability
New data presented in October 2026 shows long-term therapy maintains anti-TNF drug effectiveness for Crohn's disease patients.
Updated on Oct. 21, 2026 in Nutrition
Live Poll
Is it worth continuing long-term combination medication if it improves the durability of your primary treatment?
The PROFILE trial analysis reveals that sustained combination therapy significantly improves long-term anti-TNF treatment durability in Crohn's disease patients. Researchers presented these findings in October 2026, highlighting the risks associated with withdrawing immunomodulators.
Why it matters
The study addresses the critical challenge of maintaining response to biologic treatments over time for individuals with Crohn's disease. Understanding how immunomodulators impact therapy persistence helps clinicians optimize treatment strategies to prevent faster loss of drug effectiveness.
The study of 358 participants observed a median anti-TNF treatment persistence of 73 months. Researchers noted that sustaining combination treatment resulted in significantly higher efficacy compared to monotherapy over 5 years.
The players
PROFILE trial
This clinical study investigates treatment strategies for adults diagnosed with Crohn's disease.
United European Gastroenterology Week
This international scientific congress serves as a platform for presenting the latest research in gastrointestinal health.
The details
The PROFILE trial randomized 386 adults with newly diagnosed Crohn's disease to compare immediate top-down combination therapy against an accelerated step-up strategy. Results indicated that using immunomodulators, such as thiopurines, reduces both immunogenic and nonimmunogenic treatment failures compared to monotherapy.
Timeline
October 2026: Findings presented at United European Gastroenterology Week.
5 years: Median follow-up duration for the 358 study participants.
73 months: Median anti-TNF treatment persistence among study patients.
The Big Picture
This analysis extends the clinical understanding established by the PROFILE trial's initial randomization protocol. By tracking long-term patient records, the data clarifies the effectiveness of different immunomodulator strategies in preventing anti-TNF treatment failure.
Patients may discuss the findings regarding combination therapy and potential immunomodulator withdrawal with their gastroenterologist to better manage their Crohn's disease treatment plan. Long-term treatment persistence is a key factor in maintaining disease remission and avoiding the need for medication switches.
The takeaway
Maintaining consistent combination therapy appears to be a viable strategy for extending the effectiveness of anti-TNF drugs in Crohn's patients. Patients should consult their care team regarding the long-term implications of adjusting their current medication regimens.
Further reading
For more information on digestive health research, visit the Nutrition section.
Source note: This article includes information reported by Medscape.
Live Poll
Is it worth continuing long-term combination medication if it improves the durability of your primary treatment?
